• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AT1
Click for more information
3.33% 3.1¢

ATOMO DIAGNOSTICS LIMITED - News & Media

Market Cap $19.81M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Medical Devices

Atomo Diagnostics Limited is an Australia-based medical device company. The Company... Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Atomo Diagnostics orders HIV self-test kits for third world countries

Atomo Diagnostics (ASX:AT1), has put in a purchase order from Viatris Healthcare for HIV self-tests, valued at approximately $570,000.

15 Apr 2024 11:14 (AEST)

Atomo Diagnostics (ASX:AT1) secures $900k order for HIV self-tests

Atomo Diagnostics (ASX:AT1) has secured a $900,000 purchase order for its HIV self-tests from Newfoundland Diagnostics.

28 Feb 2023 12:49 (AEDT)

Atomo Diagnostics (ASX:AT1) signs new agreement with NG Biotech to expand launch of blood based pregnancy test

Atomo Diagnostics (ASX:AT1) has signed a new commercialisation agreement with NG Biotech SAS to expand the global launch of a blood-based rapid pregnancy test.

18 Jan 2023 20:28 (AEDT)



(20min delay)
Last
3.1¢ 		Change
0.001(3.33%) 		Mkt cap ! $19.81M
Open High Low Value Volume
3.0¢ 3.1¢ 2.9¢ $4.745K 159.6K

Buyers (Bids)

No. Vol. Price($)
1 123968 3.0¢
 

Sellers (Offers)

Price($) Vol. No.
3.1¢ 53324 2
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
3.1¢ 		  Change
0.001 ( 3.33 %)
Open High Low Volume
3.0¢ 3.1¢ 2.9¢ 32795
Last updated 15.59pm 03/05/2024 ?
AT1 (ASX) Chart

Top Stories

Infini Resources gearing up for UAV geophys survey over Portland Creek

Infini Resources has announced its execution of an application for UAV-based geophysical surveys over its Portland Creek Uranium Project.
Car EV-olution accelerates Oz into pole position As the world steers towards a more sustainable future, the surge in electric vehicle (EV) sales is turning industries upside down, and mining is no exception. Australia, famous for its treasure trove of minerals, finds itself right in the middle of this shift, which raises two questions. Firstly,...
Patagonia shares rise above 20% on lithium grades at maiden well in Argentina Patagonia Lithium shares rise above 12 percent on lithium grading nearly 600 parts per million at the first drill well of its Argentinian Formentera Lithium Project.
Lithium Universe ends the quarter charged up for Quebec Refinery roll-out Lithium Universe has closed off the March quarter with a new Chief Financial Officer and strategically located land anchored for its lithium refinery in Quebec, Canada.
BPH Energy renews NT Bonaparte Basin permit BPH Energy (ASX:BPH) announced on Friday that it has renewed a key licence in the Northern Territory (NT) overlying the Bonaparte Basin.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.